Develops synthetic biology platforms for cell and gene therapies, focusing on targeted immunotherapies.
Senti Biosciences, Inc. is an innovative biotechnology company specializing in advanced cell and gene therapies at the preclinical stage. Leveraging its cutting-edge gene circuit platform technologies, the company focuses on developing next-generation therapies for a range of diseases. Senti Biosciences' flagship product candidates feature allogeneic chimeric antigen receptor natural killer (CAR-NK) cells enhanced with its proprietary gene circuit technologies, tailored for various oncology indications.
Among its leading candidates, SENTI-202 stands out as a Logic Gated OR+NOT off-the-shelf CAR-NK cell therapy designed to selectively target and eradicate acute myeloid leukemia cells while preserving the integrity of healthy bone marrow. Additionally, SENTI-301 represents a multi-armed off-the-shelf CAR-NK cell therapy tailored for treating hepatocellular carcinoma, while SENTI-401 aims to address colorectal cancer with its Logic Gated (NOT) off-the-shelf CAR-NK cell therapy approach. These advancements highlight Senti Biosciences' commitment to pioneering targeted therapies that minimize collateral damage to healthy tissues.
Established in 2016 and headquartered in South San Francisco, California, Senti Biosciences continues to drive innovation in the biotechnology sector. The company's strategic focus on harnessing gene circuit technologies underscores its dedication to developing transformative treatments that hold promise for improving patient outcomes in oncology and beyond.